Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Bisphosphonate
•
Primary Care
Do you use bisphosphonates in combination with SERMs in female patients with progressive decline in bone density despite being on a SERM for post-menopausal symptoms other than osteoporosis?
Related Questions
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
Would you use anabolic agents (romosozumab or PTH analogues) for osteoporosis treatment in patients with CKD?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
When transitioning from anabolic agent to denosumab, do you stop teriparatide 1 day prior to transition and romosozumab 1 month prior to transition?
